The fact that metformin exerts its regulatory effect on weight via GDF15-GFRAL-RET provides proof of principle for GFRAL agonism as a therapeutic strategy in obesity. This evidence concerns the gene RET and obesity due to melanocortin 4 receptor deficiency.